| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | NULL | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | NULL | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) | NULL | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT03136419 | Microbiota and Immune microEnvironment in Pouchitis | NA | UNKNOWN | University of Padova | Pouchitis|Ulcerative Colitis|Ileal Pouch | DIETARY_SUPPLEMENT: Lactobacillus casei DG|DIETAR… | Details |
| NCT02965209 | European Novel Motorized Spiral Endoscopy Trial | NA | COMPLETED | Evangelisches Krankenhaus Düsseldorf | Disorder of Small Intestine|Gastrointestinal Hemo… | PROCEDURE: motorized spiral enteroscopy | Details |
| NCT02774057 | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer®|DRUG: Iron Sulfate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Environmental risk factors for inflammatory bowel disease
PMID: 20567592
Year: 2010
Relationship Type:
Association
Score: 9.1
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract and is associated with significant morbidity.…
Unexplained iron deficiency anaemia: Is it worthwhile to perform capsule endosc…
PMID: 20227929
Year: 2010
Relationship Type:
Treatment
Score: 9.1
BACKGROUND: In around 30% of iron deficiency anaemia (IDA) cases a definite diagnosis cannot be made. AIM: To investigate the role of capsule endosco…
Intravenous iron sucrose is superior to oral iron sulphate for correcting anaem…
PMID: 19330567
Year: 2009
Relationship Type:
Association
Score: 9.1
TM7 is a recently described subgroup of Gram-positive uncultivable bacteria originally found in natural environmental habitats. An association of th…
Managing iron deficiency and iron deficiency anemia in inflammatory bowel disea…
PMID: 29465251
Year: 2018
Relationship Type:
Treatment
Score: 8.3
BACKGROUND: Although the stem cell marker Bmi1 is overexpressed in many malignancies, its role in inflammation-associated cancer is unclear. Coliti…
Carrier-Free Nanocapsule with Dual-Target Capacity for Synergistically Restorin…
PMID: 40650704
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic inflammatory disease with limited therapeutic outcomes. Macrophages are the key gatekeepers of intestin…
The effects of candidate probiotic strains on the gut environment in dextran su…
PMID: 40593990
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and dysbiosis, with limited treatment options and si…
Iron Deficiency in Adults: A Review
PMID: 40159291
Year: 2025
Relationship Type:
Association
Score: 6.5
Letter: The Hidden Truth of IBD Risk-From Antibiotics to Environmental Factors
PMID: 39954249
Year: 2025
Relationship Type:
Association
Score: 6.5
Effect of Cu- and Fe- Isolated from Environmental Particulate Matter on Mitocho…
PMID: 39738852
Year: 2025
Relationship Type:
Association
Score: 6.5
Modifying Our Environment to Improve Outcomes in Inflammatory Bowel Diseases?
PMID: 39665504
Year: 2025
Relationship Type:
Association
Score: 6.5
Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Micr…
PMID: 39641224
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Childhood developmental environment affects adult intestinal inflammation level…
PMID: 39638766
Year: 2024
Relationship Type:
Association
Score: 6.5
Mucosal Healing in Inflammatory Bowel Diseases: Still Too Many Irons on the Fir…
PMID: 39632545
Year: 2025
Relationship Type:
Association
Score: 6.5
Exposure to Environmental Pollutants and Risk of Diarrhea: A Systematic Review
PMID: 39619770
Year: 2024
Relationship Type:
Association
Score: 6.5
Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Call to A…
PMID: 39579077
Year: 2025
Relationship Type:
Association
Score: 6.5
Myocardial iron intake following intravenous iron therapy with ferric carboxyma…
PMID: 39562805
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Mucosal Healing in Inflammatory Bowel Diseases: Still too Many Irons on the Fire
PMID: 39501422
Year: 2024
Relationship Type:
Association
Score: 6.5
Oral administration of Lactobacillus casei DG® after ileostomy closure in resto…
PMID: 39485259
Year: 2024
Relationship Type:
Association
Score: 6.5
Environmental and inflammatory factors influencing concurrent gut and lung infl…
PMID: 39432107
Year: 2024
Relationship Type:
Association
Score: 6.5
Inflammation-Responsive Polyion Complex Vesicles for Autoimmune Disease Therapy…
PMID: 39410737
Year: 2024
Relationship Type:
Treatment
Score: 6.5